Ketabon, a collaboration between HMNC Brain Health and Develco Pharma, is focused on the development of an extended-release oral formulation of ketamine for the treatment of Treatment-Resistant Depression (TRD). The key objective is to create a formulation that offers prolonged release and minimal dissociative side effects. This innovative approach has the potential to enhance the risk profile and convenience for patients, d...
Ketabon, a collaboration between HMNC Brain Health and Develco Pharma, is focused on the development of an extended-release oral formulation of ketamine for the treatment of Treatment-Resistant Depression (TRD). The key objective is to create a formulation that offers prolonged release and minimal dissociative side effects. This innovative approach has the potential to enhance the risk profile and convenience for patients, distinguishing it from existing intravenous and intranasal ketamine therapies. Ketabon is dedicated to advancing a novel and improved treatment option for individuals dealing with Treatment-Resistant Depression.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.